不同聚乙二醇化干扰素治疗丙型肝炎病毒感染临床观察

目的评价聚乙二醇化干扰素α-2a或α-2b(PEG-IFNα-2a/α-2b)联合利巴韦林治疗慢性丙型肝炎病毒感染的疗效与副作用,以优化慢性丙型肝炎治疗策略、提高临床治愈率。方法 60例慢性丙型肝炎患者随机分为A组和B组各30例,分别给予PEG-IFNα-2a加利巴韦林(A组)和PEG-IFNα-2b加利巴韦林(B组)治疗48周,检测基线及治疗4周、l2周、48周及治疗结束后24周时的血清HCV-RNA水平,比较两组快速病毒学应答(RVR)率、早期病毒学应答(EVR)率、治疗终点病毒学应答(ETVR)率、持续病毒学应答(SVR)以及复发率与不良反应。结果 A组和B组RVR、EVR、ETVR、SVR、复发率分别为46.7%、63.3%、86.7%、80.0%、6.7%和40.0%、56.7%、80.0%、76.7%、3.3%,组间比较,差异均无统计学意义(P0.05),两组的安全性情况相似,未见严重的不良事件,总体耐受性好。结论两种现有的聚乙二醇化干扰素α-2a或α-2b联合利巴韦林治疗丙型肝炎病毒感染的持续病毒学应答率和耐受性没有显著差异。

Clinical observation on peginterferon alfa-2a or alfa-2b with ribavirin for treatment of hepatitis C infection

Objective To evaluate the efficacy and side effects of peginterferon alfa-2a or alfa-2b（PEGIFNα-2a/α-2b）with ribavirin for treatment of hepatitis C infection,which could be helpful for optimizing the treatment strategy and increasing clinical recovery rate of chronic hepatitis C. Methods 60 patients with chronic hepatitis C were selected and 30 patients received PEG-IFNα-2a with ribavirin therapy for 48 works （A group） and other 30 received PEG-IFNα-2b with ribavirin therapy for 48 works （B group）,and a 24-week of follow-up was performed. HCV-RNA was detected at the baseline,4-week postmanagement,12-week postmanagement,48-week postmanagement,and 24-week after completion of a full course,respectively. The rapid virological response（RVR）rate,early virological response（EVR） rate,end of treatment virological response（ETVR）rate,sustained virological response （SVR）rate,relapse rate and adverse reactions were assessed. Results The RVR,EVR,ETVR,SVR and relapse rate in A group were 46.7%,63.3%,86.7%,80.0% and 6.7%,respectively,which were similar with thatin B group （40.0%,56.7%,80.0%,76.7% and 3.3%,respectively,P0.05）. The safety profile,adverse reactions and tolerance were also similar. Serious adverse events were not observed. Conclusion The sustained virological response and tolerance on peginterferon alfa-2a or alfa-2b with ribavirin for treatment of hepatitis C infection are similar.